The 31-gene expression profile test informs sentinel lymph node biopsy decisions in patients with cutaneous melanoma: results of a prospective, multicenter study

References

• Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma staging: evidence-based changes in the American joint committee on cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67:472–492.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer. NCCN guidelines melanoma: cutaneous. Version 2.2022. 2022.
   Google Scholar
• Morton DL, Thompson JF, Cochran AJ, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med. 2014;370:599–609.
   PubMed Web of Science ®Google Scholar
• Chen J, Xu Y, Zhou Y, et al. Prognostic role of sentinel lymph node biopsy for patients with cutaneous melanoma: a retrospective study of surveillance, epidemiology, and end-result population-based data. Oncotarget. 2016;7:45671–45677.
   PubMedGoogle Scholar
• Luke JJ, Rutkowski P, Queirolo P, et al. Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial. Lancet. 2022;399(10336):1718–1729.
   Web of Science ®Google Scholar
• Weitemeyer MB, Helvind NM, Brinck AM, et al. More sentinel lymph node biopsies for thin melanomas after transition to AJCC 8th edition do not increase positivity rate: a Danish population-based study of 7148 patients. J Surg Oncol. 2022;125:498–508.
   PubMed Web of Science ®Google Scholar
• Egger ME, Stevenson M, Bhutiani N, et al. Should sentinel lymph node biopsy be performed for all T1b melanomas in the new 8th edition American Joint Committee on cancer staging system? Journal of the American College of Surgeons. 2019;228:466–472.
   PubMed Web of Science ®Google Scholar
• Moncrieff MD, Lo SN, Scolyer RA, et al. ASO visual abstract: evaluation of indications for sentinel node biopsy in early-stage melanoma with the advent of adjuvant systemic therapy: an international multicenter study. Ann Surg Oncol. 2022;29:5946–5947.
   Web of Science ®Google Scholar
• Agnese DM, Abdessalam SF, Burak WE, et al. Cost-effectiveness of sentinel lymph node biopsy in thin melanomas. Surgery. 2003;134:542–547. discussion 547–548.
   PubMed Web of Science ®Google Scholar
• Aiken TJ, Stahl CC, Schwartz PB, et al. Sentinel lymph node biopsy is associated with increased cost in higher risk thin melanoma. J Surg Oncol. 2021;123:104–109.
   PubMed Web of Science ®Google Scholar
• Marchetti MA, Bartlett EK. Sentinel lymph node biopsy in cutaneous melanoma-where do we stand? JAMA Dermatol. 2021;157:1159–1160.
   PubMed Web of Science ®Google Scholar
• Dika E, Riefolo M, Porcellini E, et al. Defining the prognostic role of microRNAs in cutaneous melanoma. J Invest Dermatol. 2020;140:2260–2267.
   PubMed Web of Science ®Google Scholar
• Riefolo M, Porcellini E, Dika E, et al. Interplay between small and long non-coding RNAs in cutaneous melanoma: a complex jigsaw puzzle with missing pieces. Mol Oncol. 2019;13(1):74–98.
   PubMed Web of Science ®Google Scholar
• Bittner M, Meltzer P, Chen Y, et al. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature. 2000;406(6795):536–540.
   PubMed Web of Science ®Google Scholar
• Whitman ED, Koshenkov VP, Gastman BR, et al. Integrating 31-gene expression profiling with clinicopathologic features to optimize cutaneous melanoma sentinel lymph node metastasis prediction. J Clin Oncol Precision Oncology. 2021;5:1466–1479.
   Web of Science ®Google Scholar
• Hsueh EC, DeBloom JR, Lee JH, et al. Long-term outcomes in a multicenter, prospective cohort evaluating the prognostic 31-gene expression profile for cutaneous melanoma. J Clin Oncol Precision Oncology. 2021;5:589–601.
   Web of Science ®Google Scholar
• Jarell A, Skenderis B, Dillon LD, et al. The 31-gene expression profile stratifies recurrence and metastasis risk in patients with cutaneous melanoma. Future Oncol. 2021;17(36):5023–5031.
   PubMed Web of Science ®Google Scholar
• Vetto JT, Hsueh EC, Gastman BR, et al. Guidance of sentinel lymph node biopsy decisions in patients with T1–T2 melanoma using gene expression profiling. Future Oncol. 2019;15(11):1207–1217.
   PubMed Web of Science ®Google Scholar
• Arnot SP, Han G, Fortino J, et al. Utility of a 31-gene expression profile for predicting outcomes in patients with primary cutaneous melanoma referred for sentinel node biopsy. Am J Surg. 2021;221(6):1195–1199.
   PubMed Web of Science ®Google Scholar
• Moody JA, Ali RF, Carbone AC, et al. Complications of sentinel lymph node biopsy for melanoma – a systematic review of the literature. Eur J Surg Oncol. 2017;43(2):270–277.
   PubMed Web of Science ®Google Scholar
• Gerami P, Cook RW, Wilkinson J, et al. Development of a prognostic genetic signature to predict the metastatic risk associated with cutaneous melanoma. Clin Cancer Res. 2015;21(1):175–183.
   PubMed Web of Science ®Google Scholar
• Dillon LD, McPhee M, Davidson RS, et al. Expanded evidence that the 31-gene expression profile test provides clinical utility for melanoma management in a multicenter study. Curr Med Res Opin. 2022;38(8):1267–1274.
   PubMed Web of Science ®Google Scholar
• Berger AC, Davidson RS, Poitras JK, et al. Clinical impact of a 31-gene expression profile test for cutaneous melanoma in 156 prospectively and consecutively tested patients. Curr Med Res Opin. 2016;32(9):1599–1604.
   PubMed Web of Science ®Google Scholar
• Schuitevoerder D, Heath M, Cook RW, et al. Impact of gene expression profiling on decision-making in clinically node negative melanoma patients after surgical staging. J Drugs Dermatol. 2018;17(2):196–199.
   PubMed Web of Science ®Google Scholar
• Marson J, Litchman G, Svoboda R, et al. Assessment of the 31-gene expression profile test by dermatologists: a cross-sectional survey from national dermatology conferences. J of Skin. 2021;5(2):101–107.
   Google Scholar
• Scott AM, Dale PS, Conforti A, et al. Integration of a 31-gene expression profile into clinical Decision-Making in the treatment of cutaneous melanoma. Am Surg. 2020;86(11):1561–1564.
   PubMed Web of Science ®Google Scholar
• Ahmed K, Siegel JJ, Morgan-Linnell SK, et al. Attitudes of patients with cutaneous melanoma toward prognostic testing using the 31-gene expression profile test. Cancer Med. 2022. DOI:10.1002/cam4.5047
   PubMed Web of Science ®Google Scholar
• O'Neill SC, Brewer NT, Lillie SE, et al. Women’s interest in gene expression analysis for breast cancer recurrence risk. J Clin Oncol. 2007;25(29):4628–4634.
   PubMed Web of Science ®Google Scholar
• Ollek S, Minkova S, Taqi K, et al. Population-based assessment of sentinel lymph node biopsy in the management of cutaneous melanoma. cjs. 2022;65(3):E394–E403.
   Web of Science ®Google Scholar
• Gerami P, Cook RW, Russell MC, et al. Gene expression profiling for molecular staging of cutaneous melanoma in patients undergoing sentinel lymph node biopsy. J Am Acad Dermatol. 2015;72(5):780–785.e3.
   PubMed Web of Science ®Google Scholar
• Jarell A, Gastman BR, Dillon LD, et al. Optimizing treatment approaches for patients with cutaneous melanoma by integrating clinical and pathologic features with the 31-gene expression profile test. J Am Acad Dermatol. 2022;87(6):1312–1320.
   PubMed Web of Science ®Google Scholar
• Farberg AS, Glazer AM, White R, et al. Impact of a 31-gene expression profiling test for cutaneous melanoma on dermatologists’ clinical management decisions. J Drugs Dermatol. 2017;16(5):428–431.
   PubMed Web of Science ®Google Scholar
• Kwatra SG, Hines H, Semenov YR, et al. A dermatologist’s guide to implementation of gene expression profiling in the management of melanoma. J Clin Aesthet Dermatol. 2020;13:s3–s14.
   PubMedGoogle Scholar